에 대한 최신 뉴스 Ventas (NYSE:VTR) 주식

Ventas

Ventas owns a diversified healthcare portfolio of over 1,300 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.

Ventas Inc

VETROPACK HLDF ST PRX A by Vetropack Holding SA

Vitrolife AB

VECTRON SYSTEMS AG NEW by Vectron Systems AG New

Vectron Systems AG

Viatris Inc

VECTOR INC TOKYO by Vector Inc.

Vitru Ltd

Ratings for Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $67.0, a high estimate of $69.00, and a low estimate of $65.00. This current average has decreased by 0.74% from the previous average price target of $67.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1738004441_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Ventas by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$69.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$66.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Vikram Malhorta</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$68.00</td>
<td>$71.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ventas. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ventas compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Ventas's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Ventas's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VTR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ventas analyst ratings.</a>
<h2>All You Need to Know About Ventas</h2>
Ventas owns a diversified healthcare portfolio of over 1,300 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
<h3>Financial Insights: Ventas</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Ventas displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 7.52%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Ventas's net margin excels beyond industry benchmarks, reaching 1.56%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Ventas's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.2%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Ventas's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.08% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Ventas's debt-to-equity ratio is below the industry average at 1.42, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Beyond The Numbers: 4 Analysts Discuss Ventas Stock

Scotiabank analyst Nicholas Yulico maintains Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) with a Sector Perform and raises the price target from $68 to $69.

News

Price Target

Scotiabank Maintains Sector Perform on Ventas, Raises Price Target to $69

Ventas's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) short percent of float has fallen 48.99% since its last report. The company recently reported that it has 10.98 million shares sold short, which is 3.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.03 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ventas Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737658813_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ventas has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Ventas's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ventas's peer group average for short interest as a percentage of float is 7.61%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Is The Market Feeling About Ventas?

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst David Rodgers upgraded the rating for Ventas Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) from Neutral to Outperform but lowered the price target from $66 to $65. Ventas shares closed at $58.36 on Thursday. <a href="https://www.benzinga.com/quote/VTR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst James Faucette upgraded Clearwater Analytics Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) from Equal-Weight to Overweight and raised the price target from $30 to $34. Clearwater Analytics shares closed at $27.09 on Thursday. <a href="https://www.benzinga.com/quote/CWAN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Tom O&#8217;Malley upgraded Lumentum Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) from Underweight to Overweight and raised the price target from $80 to $125. Lumentum shares closed at $89.36 on Thursday. <a href="https://www.benzinga.com/quote/LITE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Fatima Boolani upgraded the rating for Cloudflare Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) from Neutral to Buy and raised the price target from $95 to $145. Cloudflare shares closed at $114.82 on Thursday. <a href="https://www.benzinga.com/quote/NET/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Andrew Didora upgraded American Airlines Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) from Underperform to Neutral and raised the price target from $12 to $20. American Airlines shares closed at $18.29 on Thursday. <a href="https://www.benzinga.com/quote/AAL/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AAL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="603" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17084648/image-122-1024x603.png" alt="" class="wp-image-739021" style="width:546px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17084648/image-122-1024x603.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17084648/image-122-300x177.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17084648/image-122-768x453.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17084648/image-122.png 1132w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Upgrades

Pre-Market Outlook

Markets

CWAN

LITE

This American Airlines Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday

Baird analyst David Rodgers upgrades Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) from Neutral to Outperform and lowers the price target from $66 to $65.

Baird Upgrades Ventas to Outperform, Lowers Price Target to $65

Baird analyst David Rodgers maintains Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) with a Neutral and raises the price target from $65 to $66.

Baird Maintains Neutral on Ventas, Raises Price Target to $66

Following this successful lease amendment, the completed closing of the 11 community International JV / Welltower Portfolio, and the expected closings of the remaining previously-announced acquisition of 30 communities
<ul>
<li>Following this successful lease amendment, the completed closing of the 11 community International JV / Welltower Portfolio, and the expected closings of the remaining previously-announced acquisition of 30 communities from two additional currently leased portfolios, the Company has largely cleared its lease maturities through 2029. After giving effect to these transactions, Brookdale will own over 75% of its consolidated units, marking another significant step in the Company's efforts to increase its owned real estate portfolio, benefiting from the economics of ownership, while substantially improving the cash flow profile and reducing risk associated with its overall leased portfolio.</li>
<li>The Company expects the Ventas lease amendment to provide a $15+ million improvement to the Company's 2025 cash flows.(1) Beginning in 2026, the Company expects additional cash flow improvement, including continued operating income growth, the benefit of continued appropriate expense management relative to the Company's portfolio size, partially offset by incremental rent expense.</li>
</ul>

Health Care

General

Brookdale Senior Living Has Entered Into Mutually Beneficial Agreements With Ventas To Amend Its Triple-Net Master Lease Arrangement, Which Can Potentially Provide Over $15M Improvement To The Company's 2025 Cash Flows

Ventas's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) short percent of float has risen 161.6% since its last report. The company recently reported that it has 21.48 million shares sold short, which is 6.88% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.76 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ventas Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733770823_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ventas has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ventas's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ventas's peer group average for short interest as a percentage of float is 6.94%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Ventas's Recent Short Interest

Throughout the last three months, 5 analysts have evaluated Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Ventas and provided 12-month price targets. The average target is $69.0, accompanied by a high estimate of $71.00 and a low estimate of $65.00. Witnessing a positive shift, the current average has risen by 8.15% from the previous average price target of $63.80.
<img src="https://www.benzinga.com/files/images/story/2024/1733407325_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Ventas among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vikram Malhorta</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$68.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$65.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>John Kilichowski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$71.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$71.00</td>
<td>$64.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ventas. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Ventas compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Ventas's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Ventas's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/VTR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ventas analyst ratings.</a>
<h2>Get to Know Ventas Better</h2>
Ventas owns a diversified healthcare portfolio of over 1,300 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
<h3>Financial Milestones: Ventas's Journey</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Ventas's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 7.52%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Ventas's net margin excels beyond industry benchmarks, reaching 1.56%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Ventas's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.2%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Ventas's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.08% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Ventas's debt-to-equity ratio is below the industry average. With a ratio of 1.42, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Ventas Stands With Analysts

Mizuho analyst Vikram Malhorta maintains Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) with a Outperform and lowers the price target from $71 to $68.

Mizuho Maintains Outperform on Ventas, Lowers Price Target to $68

Offerings

Ventas Announces Prices $677M Underwritten Offering Of 10.6M Shares Of Common Stock

Ventas Announces Underwritten Offering Of 10.6M Shares of Common Stock

Ventas's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) short percent of float has fallen 18.37% since its last report. The company recently reported that it has 8.34 million shares sold short, which is 2.71% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.72 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ventas Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730747717_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ventas has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Ventas's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ventas's peer group average for short interest as a percentage of float is 7.28%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Guidance

Ventas Sees FY24 FFO $3.14-$3.18 Vs $3.17 Estimate

Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) reported quarterly earnings of $0.80 per share which met the analyst consensus estimate. The company reported quarterly sales of $1.24 billion which beat the analyst consensus estimate of $1.21 billion by 1.86 percent. This is a 7.48 percent increase over sales of $1.15 billion the same period last year.

Earnings

Earnings Beats

Ventas Q3 2024 GAAP EPS $0.80, Inline, Sales $1.24B Beat $1.21B Estimate

Welltower, Inc. WELL&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/well#NYSE">WELL</a>) is slated to report <a href="https://www.zacks.com/stock/research/WELL/earnings-calendar?icid=quote-stock_overview-quote_nav_tracking-zcom-left_subnav_quote_navbar-earnings_dates_announcements">third-quarter 2024 results</a> on Oct. 28, after market close. The quarterly results are likely to reflect year-over-year growth in revenues and funds from operations (FFO) per share.
In the last reported quarter, this Toledo, OH-based healthcare real estate investment trust (REIT) witnessed a normalized FFO per share of $1.05, beating the Zacks Consensus Estimate by 5%. Results reflected a rise in revenues on a year-over-year basis. The total portfolio same-store net operating income (SSNOI) increased year over year, driven by SSNOI growth in the senior housing operating (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sho#NYSE">SHO</a>) portfolio.
Over the preceding four quarters, Welltower&#39;s FFO per share beat the Zacks Consensus Estimate on each occasion, the average beat being 4.49%. The graph below depicts this surprise history:
<div class="chart_embed">
<h3>Welltower Inc. Price and EPS Surprise</h3>
<a href="https://www.zacks.com/stock/chart/WELL/price-eps-surprise?icid=chart-WELL-price-eps-surprise"><img alt="Welltower Inc. Price and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/26/1729610764.png" style="height:301px; width:624px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/WELL/price-eps-surprise?icid=chart-WELL-price-eps-surprise">Welltower Inc. price-eps-surprise</a> | <a href="https://www.zacks.com/stock/quote/WELL?icid=chart-WELL-price-eps-surprise">Welltower Inc. Quote</a>
</div>
<h3>Factors At Play</h3>
Welltower owns a diversified portfolio in the healthcare real estate industry in the major, high-growth markets of the United States, Canada, and the U.K.
During the third quarter, the company&#39;s SHO portfolio is likely to have continued to benefit from an aging U.S. population and a rise in healthcare expenditure by this age cohort, which is usually on the higher end compared with the general population. In addition, muted new supply is expected to have provided a favorable operating environment for the SHO portfolio.
Further, Welltower&#39;s long-term leases with its healthcare management companies or operators are anticipated to have led to stable revenue generation, boosting its top line.
The Zacks Consensus Estimate for third-quarter resident fees and services is pegged at $1.44 billion, indicating an increase from the year-ago quarter&#39;s $1.2 billion. The consensus mark for quarterly rental income stands at $411.4 million, implying a rise from $384.5 million in the year-ago period.
The Zacks Consensus Estimate for quarterly total revenues is pegged at $1.95 billion, suggesting a rise of 17.3% from the prior-year period&#39;s reported number.
We expect WELL to have continued with its investment and development activities during the quarter, supported by its solid balance sheet position and capital-recycling efforts.
However, high interest expenses are likely to have been a spoilsport for Healthpeak during the to-be-reported quarter.
WELL&#39;s activities during the quarter were inadequate to garner analysts&#39; confidence. The Zacks Consensus Estimate for third-quarter FFO per share has remained unrevised at $1.04 over the past month. However, the figure suggests an increase of 13% from the year-ago reported number.
<h2>What Our Quantitative Model Predicts</h2>
Our proven model does not conclusively predict a likely beat in terms of FFO per share for Welltower this season. The combination of a positive <a href="https://www.zacks.com/earnings/earnings-surprise-predictions/">Earnings ESP</a> and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the chances of an FFO beat, which is not the case here.
Welltower currently has an Earnings ESP of 0.00% and carries a Zacks Rank of 2. You can uncover the best stocks to buy or sell before they&#39;re reported with our <a href="https://www.zacks.com/premium/esp-buy?adid=zp_article_espfilter&amp;icid=zpi_article_espfilter">Earnings ESP Filter</a>.
<h3>Other Stocks That Warrant A&nbsp;Look</h3>
Here are two other stocks from the broader REIT sector &mdash; Extra Space Storage EXR and Ventas VTR &mdash; you may want to consider as our model shows that these, too, have the right combination of elements to report a surprise this quarter.
Extra Space Storage, scheduled to report quarterly numbers on Oct. 29, has an Earnings ESP of +0.67% and carries a Zacks Rank of 3.
Ventas, slated to release quarterly numbers on Oct. 30, has an Earnings ESP of +0.97% and carries a Zacks Rank of 2 at present.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO), a widely used metric to gauge the performance of REITs.
<h2>Infrastructure Stock Boom To Sweep America</h2>
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It&#39;s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is &quot;Will you get into the right stocks early when their growth potential is greatest?&quot;
<a href="https://www.zacks.com/stock/news/2355232/welltower-stock-to-report-q3-earnings-what-s-in-the-cards?cid=CS-BENZ-FT-analyst_blog|earnings_preview-2355232">To read this article on Zacks.com click here.</a>

REIT

Real Estate

WELL

Welltower Stock To Report Q3 Earnings: What's In The Cards?

Ventas's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) short percent of float has risen 4.08% since its last report. The company recently reported that it has 10.20 million shares sold short, which is 3.32% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.78 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ventas Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729170919_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ventas has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ventas's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ventas's peer group average for short interest as a percentage of float is 7.25%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Ventas's Recent Short Interest

In the preceding three months, 9 analysts have released ratings for Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $64.78, a high estimate of $71.00, and a low estimate of $56.00. This current average reflects an increase of 11.48% from the previous average price target of $58.11. 
<img src="https://www.benzinga.com/files/images/story/2024/1728662429_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Ventas. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$65.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>John Kilichowski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$71.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$71.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$64.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$63.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$59.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$64.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$56.00</td>
<td>$53.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ventas. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Ventas compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Ventas's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Ventas's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/VTR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ventas analyst ratings.</a>
<h2>Discovering Ventas: A Closer Look</h2>
Ventas owns a diversified healthcare portfolio of over 1,300 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
<h3>Unraveling the Financial Story of Ventas</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Positive Revenue Trend: Examining Ventas's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.55% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Ventas's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.61% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.2%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Ventas's ROA stands out, surpassing industry averages. With an impressive ROA of 0.08%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Ventas's debt-to-equity ratio is below the industry average. With a ratio of 1.39, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 9 Ratings For Ventas

Scotiabank analyst Nicholas Yulico maintains Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) with a Sector Perform and raises the price target from $59 to $65.

Scotiabank Maintains Sector Perform on Ventas, Raises Price Target to $65

Wells Fargo analyst John Kilichowski assumes Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) with a Overweight rating and raises Price Target to $71.

Initiation

Wells Fargo Assumes Ventas at Overweight, Raises Price Target to $71

Baird upgraded Ventas (VTR) to Outperform from Neutral with a price target of $65, down from $66. The analyst believes Ventas is favorably position...

Ventas upgraded to Outperform from Neutral at Baird

Ventas trades higher after Baird's upgrade on improved fundamentals

As the healthcare real estate market flourishes, fueled by demographic transformations and cutting-edge advancements in healthcare delivery, fundamentally robust stalwarts like Welltower (WELL), Ventas (VTR), and Omega Healthcare Investors (OHI) shine as premier investment opportunities. Dive deeper to discover how these REITs are shaping the future while delivering healthy returns... The healthcare real estate sector has emerged as a dynamic investment avenue, fueled by an aging population, rising demand for specialized medical facilities, and technological advancements. Healthcare REITs, which invest in properties like senior housing, medical offices, and outpatient centers, are benefiting from robust growth driven by demographic trends and the increasing prevalence of telemedicine.
So, it could be an ideal time to scoop up leading REIT stocks Welltower Inc. (<a href="https://stocknews.com/stock/WELL/">WELL</a>), Ventas, Inc. (<a href="https://stocknews.com/stock/VTR/">VTR</a>), and Omega Healthcare Investors, Inc. (<a href="https://stocknews.com/stock/OHI/">OHI</a>), which are capitalizing on new trends, providing robust dividend yields and attracting investor interest.
Additionally, the sector's resilience during the COVID-19 pandemic underscored the value of modern, adaptable facilities, further attracting institutional capital. Emerging markets, including Asia Pacific and Latin America, are also seeing growth due to rising incomes and government investments in healthcare.
The global healthcare real estate market is projected to grow at a <a href="https://www.grandviewresearch.com/industry-analysis/healthcare-real-estate-market-report">7.9% CAGR</a> through 2030.
Considering this upward trend, let's delve into the details of <a href="https://stocknews.com/category/reits-healthcare/">REITs - Healthcare</a> stocks:
Stock #3: Ventas, Inc. (<a href="https://stocknews.com/stock/VTR/">VTR</a>) 
VTR is a leading REIT specializing in senior housing, medical buildings, and healthcare facilities across North America and the UK. Leveraging its operational expertise and Ventas OI platform, the company supports the aging population while driving growth and delivering strong financial performance.
On December 10, VTR announced a quarterly dividend of $0.45 per common share. The dividend will be paid in cash on January 16, to shareholders of record as of December 31, 2024. It pays an annual dividend of $1.80, which translates to a dividend yield of 3.16% at the prevailing price levels. Its four-year average dividend yield is 3.63%.
In the fiscal third quarter ended September 30, 2024, VTR's total revenues increased 7.5% year-over-year were $1.24 billion. In addition, the net income attributable to common stockholders came in at $19.24 million and $0.05 per share, compared to a loss of $71.12 million and $0.18 per share in the prior year quarter, respectively.
Street expects VTR's <a href="https://www.investopedia.com/terms/r/revenue.asp">revenue</a> for the fiscal fourth quarter (ending December 31, 2024) to increase 7.7% year-over-year to $ 1.25 billion. Its FFO for the same quarter is expected to increase 5.7% year-over-year to $0.80. In addition, it surpassed the consensus revenue and FFO estimates in all of the trailing four quarters, which is promising.
Shares of VTR have gained 17.2% over the past year and 10% over the past six months to close the last trading session at $57.07.
VTR's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its robust outlook. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.
VTR has a B grade in Growth and Stability. It is ranked #9 out of 14 stocks in the <a href="https://stocknews.com/category/reits-healthcare/">REITs - Healthcare</a>.
Beyond what we have stated above, we also have given VTR grades for Value, Momentum, Sentiment, and Quality. Get all the VTR's ratings <a href="https://stocknews.com/stock/VTR/">here</a>.
Stock #2: Welltower Inc. (<a href="https://stocknews.com/stock/WELL/">WELL</a>) 
WELL is a REIT that focuses on transforming healthcare infrastructure by investing in seniors housing, post-acute communities, and outpatient medical properties across high-growth markets in the U.S., Canada, and the UK.
It pays an annual dividend of $ 2.68, which translates to a dividend yield of 2.16% at the prevailing price levels. Its four-year average dividend yield is 2.94%. The company has grown its dividend payment at a CAGR of 1.6% over the past three years.
During the fiscal third quarter that ended September 30, 2024, WELL's total revenues increased 23.7% year-over-year to $2.06 billion. In addition, the company's net income attributable to common stockholders and net income attributable to common stockholders per share came in at $ 449.85 million and $0.73, up 252.9% and 204.2% over the prior-year quarter, respectively.
Analysts expect WELL's revenue and FFO for the fourth quarter ending December 31, 2024, to increase 25.1% and 16.7% year-over-year to $ 2.19 billion and $ 1.12, respectively. In addition, it surpassed the consensus revenue estimates in all of the trailing four quarters.
Shares of WELL have gained 38.3% over the past year and 19% over the past six months to close the last trading session at $124.24.
WELL's POWR Ratings reflect its robust outlook. It has an A grade for Sentiment and a B in Growth. It is ranked #8 in the same industry.
Click <a href="https://stocknews.com/stock/WELL/">here</a> to see WELL's ratings for Value, Momentum, Stability, and Quality.
Stock #1: Omega Healthcare Investors, Inc. (<a href="https://stocknews.com/stock/OHI/">OHI</a>) 
OHI is a REIT specializing in financing and capital for the long-term healthcare sector, focusing on skilled nursing facilities across the U.S. and the UK. OHI partners with 81 operators to identify quality healthcare investments offering optimal risk/reward for investors.
It pays an annual dividend of $2.68, which translates to a dividend yield of 7.18% at the prevailing price levels. Its four-year average dividend yield is 8.40%.
OHI's total revenues increased 14% year-over-year to $276.03 million in the fiscal third quarter that ended on September 30, 2024. Its adjusted funds from operations came in at $ 203.07 million, up 11.5% year-over-year. Moreover, its net income available to common stockholders and earnings per common share available to common stockholders stood at $ 111.76 million and $0.42, up 22.3% and 13.5% over the prior-year quarter, respectively.
The market projects OHI's revenue for the fiscal fourth quarter (ending December 31, 2024) to increase 10.9% year-over-year to $226.28 million. Its FFO for the same quarter is likely to increase 6.4% year-over-year to $0.72. In addition, it surpassed the consensus FFO estimates in each of the trailing four quarters.
Shares of OHI have gained 20.1% over the past year and 9.2% over the past six months to close the last trading session at $36.89.
OHI's bright prospects are apparent in its POWR Ratings. It has a B for Quality. It is ranked #4 in the same industry.
Click <a href="https://stocknews.com/stock/OHI/">here</a> to see OHI's ratings for Growth, Momentum, Value, Stability, and Sentiment.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
WELL shares fell $0.14 (-0.11%) in premarket trading Wednesday. Year-to-date, WELL has declined -1.42%, versus a 0.44% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Kritika Sarmah</h2> <img src='https:/wp-content/uploads/2022/08/Kritika-Sarmah_Image-3.jpg' style="float:left; padding:5px;width:125px;">Her interest in risky instruments and passion for writing made Kritika an analyst and financial journalist. She earned her bachelor's degree in commerce and is currently pursuing the CFA program. With her fundamental approach, she aims to help investors identify untapped investment opportunities.<a href="https://stocknews.com/authors/?author=kritika-sarmah">More...</a>The post <a href=https://stocknews.com/news/well-vtr-ohi-3-healthcare-reits-offering-healthy-dividend-yields/>3 Healthcare REITs Offering Healthy Dividend Yields</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare REITs Offering Healthy Dividend Yields

Baron Real Estate Income Fund Q4 2024 Shareholder Letter

Davis Real Estate Fund 2025 Annual Review

My Biggest Losses Of 2024

How The 'Smart Money' Is Investing In REITs Right Now

Morning In America

Scotiabank raised the firm's price target on Ventas (VTR) to $69 from $68 and keeps a Sector Perform rating on the shares. The firm has updated its...

Ventas price target raised to $69 from $68 at Scotiabank

AGNC

AGNCL

AGNCM

AGNCN

AGNCO

AGNCP

AHTR

BCAP

BLDG

BROE

BXMT

CORLQ

CORRQ

CUBE

DWVYF

EPRT

EQIX

FREL

GDHLF

GMRE

GOOD

GOODN

GOODO

GPEAF

GQRE

HAUS

HAUZ

HOMZ

IFGL

ILPT

INDS

INVH

IRET

KBWY

MORT

NAIL

NETL

NURE

NXRT

OPINL

PECO

PFFR

PGRE

PLDGP

PLYM

PPTY

RDOG

REET

REGCO

REGCP

REXR

RIET

SBAC

SCHH

SILA

SRVR

STAG

STWD

USRT

VIOO

VRAI

XLRE

Press Releases

Ventas Reports 2024 Third Quarter Results

Ventas Announces Underwritten Offering of 10.6 Million Shares of Common Stock

Ventas Announces Pricing of an Underwritten Offering of 10.6 Million Shares of Common Stock

Ventas to Participate in Investor Meetings at Nareit's REITworld 2024 Annual Conference

Ventas Earns Nareit 2024 Healthcare "Leader in the Light" Award

Ventas Comments on Master Lease with Brookdale Senior Living

Ventas Declares Fourth Quarter 2024 Dividend of $0.45 Per Common Share

Ventas Reaches Mutually Beneficial Agreements with Brookdale Senior Living

Ventas Announces Fourth Quarter 2024 Earnings Release Date and Conference Call

Ventas Announces Tax Treatment Of 2024 Distributions

American Healthcare REIT, Inc. Common Stock

American Healthcares

Alexandria Real Estate Equities, Inc. Common Stock

Alexandria Real Estate

Community Healthcare Trust Incorporated Common Stock

Community Healthcare

CareTrust REIT

Diversified Healthcare Trust - Common Shares of Beneficial Interest

Diversified Healthcare

Healthpeak Properties

Global Medical REIT

Healthcare Realty Trust Incorporated Common Stock

Healthcare Realty Trust

LTC Properties

Medical Properties Trust, Inc. common stock

Medical Properties Trust

National Health Investors, Inc. Common Stock

National Health Investors

Omega Healthcare Investors, Inc. Common Stock

Omega Healthcare Invts

Sabra Health Care REIT, Inc. - Common Stock

Sabra Health Care REIT

Sila Realty Trust

Strawberry Fields REIT, Inc. Common Stock

Strawberry Fields REIT

Universal Health Realty Income Trust Common Stock

Universal Health Realty

Welltower

Scotiabank

Baird

Mizuho

Wells Fargo

Evercore ISI Group

Comments

Ventas

뉴스

에 대한 최신 뉴스 Ventas (NYSE:VTR) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌